Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss

Reuters

2025/12/04

Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss

Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596658-en) on December 04, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2588884143"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588884143\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588884143?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588884143","market":"us","top_or_hot":-1,"title":"Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596658-en) on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbsci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-04 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596658-en) on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL367TTr:1","article_id":"2588884143","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588884143","pubTimestamp":1764853216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor  antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","BK4121":"生命科学工具和服务","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","ABSI":"Absci Corporation.","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4539":"次新股","BK4112":"金融交易所和数据"},"translate_title":"Absci在人工智能设计的脱发抗体1/2期试验中为第一批志愿者注射药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":0.9,"NDAQ":0.9},"content_text":"Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss\n    \n\n        Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596658-en) on December 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}